Objective Combining 18 F-FDG PET with whole-body MR for paediatric cancer staging is practically feasible if imaging protocols can be streamlined. We compared 18 F-FDG PET/ STIR with accelerated 18 F-FDG PET/FSPGR for wholebody tumour imaging in children and young adults. Methods Thirty-three children and young adults (17.5 ± 5.5 years, range 10-30) with malignant lymphoma or sarcoma underwent a 18 F-FDG PET staging examination, followed by ferumoxytol-enhanced STIR and FSPGR whole-body MR. 
Introduction
Accurate staging of malignant tumours in children and adolescents is critical to estimate prognosis and initiate appropriate cancer treatment [1] [2] [3] . 18 F-FDG positron emission tomography (PET)/computed tomography (CT) examinations are the current staging procedure of choice for the majority of paediatric patients with lymphomas and for some patients with sarcomas [4] . However, 18 F-FDG PET/CT examinations are associated with considerable radiation exposure [5] [6] [7] . We recently reported that radiation-free whole-body magnetic resonance imaging (MRI) scans provide equivalent information for cancer staging compared to studies can provide an interim alternative for tumour restaging through an imaging process that exposes young patients to significantly less radiation than PET/CT and includes metabolic and anatomical information for therapy response assessment [9, 10] . A recent study reported that coregistration of 18 F-FDG PET data with MR scans instead of CT scans allowed for whole-body staging of children with 80 % reduced radiation exposure. However, previous PET/ MR whole-body staging protocols for children were limited by using T2-weighted sequences for anatomical coregistration of PET data, which led to significantly increased scan times compared to a PET/CT examination [11] . Although PET/MRI offers improved soft tissue contrast compared to CT [12] [13] [14] [15] and allows for primary tumour and whole-body staging in one session [16] , two potential concerns have previously inhibited implementation of faster T1-weighted sequences: (1) Inability to delineate vessels over the duration of a wholebody scan due to the relatively short blood-half live of standard small molecular galodinium chelates and (2) Difficulties to align PET data (obtained through free breeching data acquisitions) with breath-hold MRI scans after deep inspiration.
We propose to solve these problems by using the blood pool agent ferumoxytol for long-lasting vascular enhancement and end-expiration breath-hold T1-weighted sequences for co-registration with 18 F-FDG PET data. Ferumoxytol is a US Food and Drug Administration (FDA)-approved iron supplement composed of ultra-small super-paramagnetic iron oxide nanoparticles which can be used 'off label' as a contrast agent for MRI [17] [18] [19] [20] . The goal of our study was to compare the time-efficiency, cost-efficiency and diagnostic accuracy of fused 18 F-FDG PET/Short TI inversion recovery (STIR) and 18 F-FDG PET/fast spoiled gradient recalled echo (FSPGR) examinations for whole-body tumour staging. Through our analysis, we have concluded that ferumoxytol-enhanced breath-hold T1-weighted FSPGR scans substantially expedite acquisition of anatomical background information, improve diagnostic cost-efficiency, and provide equal imaging specificity and sensitivity for whole-body PET/MR staging of paediatric patients and young adults. This reduction in image acquisition time makes the 18 F-FDG PET/FSPGR examination a clinically feasible staging alternative for diagnosing children and young adults with cancer.
Materials and methods

Patients
This prospective, non-randomized study was approved by the institutional review board (IRB, the local ethics committee) and the cancer center at our institution and written informed consent was obtained from all individual participants and their parents (in case of minors) included in the study. We investigated 33 patients with malignant lymphomas (n = 27) and malignant sarcomas (n = 6) including 24 males and nine females with a mean age of 17.5 ± 5.5 years (range 10-30 years). Table 1 shows age, gender and tumour type of all patients. Twenty-one of the 33 patients were part of a previously reported study on whole-body diffusion-weighted MRI. To provide accelerated cancer staging, the goal of our current study was to compare the sensitivities and specificities of two different PET/MR techniques for cancer staging, namely 18 F-FDG PET/FSPGR and 18 F-FDG PET/STIR sequences. Inclusion criteria were: (1) age between 8 and 30 years, (2) newly diagnosed lymphoma or sarcoma and (3) scheduled or completed 18 F-FDG PET/CT. All tumours were evaluated before the start of therapy. The lower age threshold of 8 years was chosen to avoid the need for sedation or anaesthesia. Exclusion criteria were: (1) MR-incompatible metal implants, (2) claustrophobia, (3) hemosiderosis/haemochromatosis and (4) history of allergies to iron products or any history of severe anaphylactic reactions. F-FDG, an emission PET was acquired of the whole body. PET images were attenuation corrected by low-dose CT data, reconstructed with a standard iterative algorithm and reformatted into axial, coronal and sagittal views.
Whole-body MRI
MRI was performed on a 3 T Discovery 750 magnetic resonance scanner (GE Healthcare). We obtained investigational new drug approval from the FDA (IND111,154) to use the FDA-approved iron supplement ferumoxytol (Feraheme™, Fe5874 O8752-C11719 H18682 O9933 Na414; AMAG Pharmaceuticals, Inc.) [21] 'off-label' as a contrast agent for MRI in children and young adults. Ferumoxytol is composed of semi-synthetic carbohydrate-coated super paramagnetic iron oxide nanoparticles with a molecular weight of 731 kDa, a hydrodynamic particle diameter of 30 nm [22] , and a long plasma half-life of 15 h. Due to their superparamagnetic properties, ferumoxytol nanoparticles give positive contrast on T1-weighted MR images and negative contrast on T2-weighted MR images [23] . All patients received an intravenous injection of ferumoxytol at a dose of 5 mg Fe/kg body weight before their MRI scan over a minimum of 15 min. [24] A personalized approach was used to ensure minimal scan time for every patient. Before the scan, each patient practiced guided breath-holding and we recorded their maximum breath-hold interval, which ranged between 20 and 35 s. The minimal field-of-view (FOV) that encompassed the patient was used, which ranged from 20-50 cm. Repetition times (TRs) and echo times (TEs) were adjusted to ensure a constant signal-to-noise ratio (SNR) for all patients. Breathhold fat-saturated T1-weighted FSPGR sequences were obtained with a flip angle of 15 o , a TR of 7-12 ms, a TE of 1-3 ms and an acceleration factor of 2. This parallel imaging acceleration required Array Spatial Sensitivity Encoding Technique (ASSET) calibration. STIR sequences were obtained with a TR of 4,000-8,000 ms and a TE of 50-60 ms. All sequences were obtained with a single acquisition, a bandwidth of 31 kHz, a slice thickness of 4-5 mm, and an image matrix of 256 × 192. Voxel dimensions amongst our acquisitions did not exceed 2.5 mm in-plane by 5 mm through-plane, and were sufficiently small to detect lymph nodes that met the clinical criterion for radiological diagnosis (15 mm mediastinal and 10 mm superficial lymph nodes).
To generate whole-body images that integrate the functional and anatomical information of the acquired 18 F-FDG and whole-body MRI scans, we post-processed our images using OsiriX software [25] . 18 F-FDG PET images were colourrendered by applying the 'PET' CLUT followed by fusion with grey-scale ferumoxytol-enhanced anatomical STIR and T1-weighted FSPGR images. F-FDG PET/FSPGR scans of each patient were evaluated in random order in separate sessions, which were separated by at least 2 months in order to avoid recall bias. In order to further minimize recall bias, the reviewers were blinded to histopathology, staging outcome, disease history and other imaging findings. Histopathology, as well as clinical and imaging follow-up for at least 6 months served as the standard of reference. All primary tumours were confirmed by histopathology. Sixty-two regions assessed in each patient (n = 33) are specified as: In addition, whole-body image acquisition times were recorded for each patient as: (a) the MR scan-time per single anatomical site, the total whole-body scan-time as well as (b) the combined time for coil placement, localizer sequence, ASSET calibration and whole-body MR sequence. F-FDG PET, which showed normal homogenous ferumoxytol-enhancement on STIR images and was confirmed as normal bone marrow by bone marrow biopsy (Fig. 2) . False-negative findings included one bone lesion and one lung nodule as shown in Fig. 3 .
Sensitivity and specificity were 99.3 % and 99.8 % for Figure 4a shows the total scan-time for FSPGR and STIR scans. Figure 4b demonstrates that the scantime per anatomical site for accelerated FSPGR (0.52 ± 0.07 min) is considerably shorter than STIR (6.2 ± 0.9 min), p < 0.001. In addition, the time for localizer, coil placement, ASSET calibration and pure MR scan are illustrated in Fig. 4c .
The imaging cost in our institution for whole-body MR scan is US$627 per hour plus US$70 per examination for technicion support, thus accelerated whole body MRI with FSPGR sequences cost on average 19.8 min × US$627/h + US$70 = US$276.91, which is less than whole body MRI with STIR sequences that costs on average 29.0 min × US$627/h + US$70 = US$373.05.
Discussion
Different sequences are typically used in whole-body MRI for monitoring tumours in children and young adults, including STIR, T2-weighted fast spin-echo sequences, diffusionweighted images (DWI) and gadolinium-enhanced T1-weighted gradient echo sequences. STIR has been the most commonly used sequence in whole-body MRI and can be performed in less than 30 min [26] [27] [28] . Our data show that ferumoxytol-enhanced 18 F-FDG PET/FSPGR examinations provide equal sensitivity and specificity compared to 18 F-FDG PET/STIR examinations with improved time-and cost-efficiency. PET/MR combines the high anatomical resolution and soft tissue contrast of MRI with the high sensitivity of PET, thereby overcoming the limited sensitivity of traditional MRI approaches and concerns regarding radiation exposure of paediatric patients from PET/CT scans [29] [30] [31] [32] . Through these benefits, patient quality of life (QoL) is purportedly enhanced by providing equivalent diagnostic information with reduced patient dose.
We acquired MR images after administration of the iron supplement ferumoxytol, in order to achieve long-lasting blood pool enhancement of vessels throughout the duration of the whole body scan. [8] . Perhaps one could compare the combination of contrast-enhanced SPGR sequences and FDG-PET scans to combining a diagnostic CT and FDG-PET scans, rather than low-dose CT scans for attenuation correction only. Ferumoxytol is a 'blood pool agent' and has a blood half-life of 15 h in humans, which allows for longlasting vessel enhancement on MR images [33] . Therefore, it is not crucial for the quality of the imaging scan to administer the contrast agent while the patient is in the scanner or to start a post-contrast scan immediately after contrast media administration. This is a convenient feature for clinical applications in paediatric patients, where timing of contrast agent injections and scanning cannot always be reliably planned. In addition, ferumoxitol uptake by the reticuloendothelial system improves tumour-to-background contrast in liver, spleen and bone marrow.
Integrated PET/MR scanners are expensive and may not be affordable for many paediatric imaging centres. Our data also show that image registration of sequentially acquired 18 F-FDG PET and MR scans is a feasible alternative. The proposed breath-hold T1-weighted SPGR sequence can be F-FDG PET/FSPGR (ellipse), and (e) hypermetabolic hematopoetic bone marrow on fused 18 F-FDG PET/STIR examinations equally used to expedite whole-body MRI data acquisition of sequential or integrated PET/MR technologies. We utilized OsiriX for image data fusion which allows for image coregistration within less than 500 μm [34] . Others have confirmed the feasibility of this approach [35] [36] [37] . Using sequential imaging approaches takes advantage of CT-based attenuation correction of PET data, while integrated scans require MR-based attenuation correction. Our ongoing studies on an integrated PET/MR scanner confirm that the same approach described here can be used for integrated ferumoxytolenhanced 18 F-FDG PET/MR scans. Both ferumoxytol-enhanced T1-weighted FSPGR and STIR sequences have some limitations due to specific artefacts: On STIR images, artefacts from breath motion in the singleaverage acquisition was noted. On the T1-weighted FSPGR images during breath-hold, cardiac motion artefacts were apparent, but more confined than the pervasive artefacts from the free breathing acquisition. Using large field-of-views for whole body scanning may lead to incomplete fat saturation at the edge of the coil. Also, the calibration and ASSET scans can in principle cause uncorrected aliasing and reduce SNR, although we did not encounter any major artefacts of this nature.
Of note, we injected ferumoxytol directly before the MRI scans. This was technically convenient and provided strong vascular enhancement, similar to the procedure of a contrastenhanced CT scan. Our previous studies showed that the vascular enhancement improved tumour delineation compared to unenhanced scans [8] . However, this relatively early postcontrast time point was too early to achieve enhancement of tumours or lymph nodes, which is strongest at 24 h post injection [38, 39] . Further studies are needed to determine whether the added diagnostic information for lymph node characterization justifies a two-step visit (day 1 for contrast injection and day 2 for MRI).
Our proposed approach requires injection of an iron oxide nanoparticle compound. The European radiological community has extensive clinical experience with these compounds and our team has applied various iron oxide nanoparticle compounds as MR contrast agents in phase I-IV clinical trials [40] [41] [42] [43] [44] . These agents are generally well tolerated and show excellent safety profiles [45] [46] [47] [48] . Considering a ferumoxytol dose of 5 mg/kg and a concentration of 30 mg Fe/ml, we anticipate injecting 250-400 mg Fe in a young adult with an average body weight of 50-80 kg (of note, these are coated iron particles, not free iron). This iron dose is lower than the FDA-approved ferumoxytol dose for anaemia treatment and comparable to the iron dose administered with one blood transfusion. Anaphylaxis or anaphylactoid reactions to ferumoxytol were reported in 0.1-0.2 % of exposed adult patients, which is comparable to other MR contrast agents. Ferumoxytol is not excreted via the kidneys and thus not associated with any risk of nephrogenic sclerosis (a potential adverse event with Gd-chelates) [19, 49, 50] . In addition, ferumoxytol may represent an alternative to the recently reported deposition of Gd-chelates in the brain [51] , although no comparative information is available so far regarding ferumoxytol deposition in the brain. Iron oxide nanoparticles are not approved for clinical use in children and applications in the USA are done through an investigational new drug (IND) application with the FDA. Safety data in paediatric patients are limited, but have not shown clinically significant side effects so far [52, 53] . The recently renewed safety discussion around iron products does not relate to new toxic effects [24] , but has to be taken seriously and has led to a 'black box' warning by the FDA. Our team currently investigates the underlying pathophysiology of anaphylactic reactions to iron oxide nanoparticles, which will hopefully enable preventive actions in the future.
Although recent advances in MRI sequences for pulmonary imaging do allow for detection of pulmonary nodules, there is a potential to miss small pulmonary lesions on MR scans which are more conspicuous with CT. Previous investigators' findings are in accordance with our results [54, 55] . Future technical improvements may overcome this limitation [56, 57] .
Focal and multifocal bone marrow infiltration shows only a minor or no iron oxide uptake, while normal hematopoietic bone marrow shows substantial iron oxide uptake. Therefore, normal and neoplastic marrow can be differentiated on ferumoxytol-enhanced STIR images, which can help to correctly identify false-positive, hypermetabolic hematopoietic bone marrow on PET scans. The bone marrow iron enhancement is detectable over a wide range of magnetic field strengths, from 1.5-7 Tesla [41] .
We recently reported a radiation-free approach for wholebody tumour staging with MRI which relied on fusion of colour-encoded diffusion-weighted MRI sequences with anatomical FSPGR sequences [8] . To date, clinical decisions for treatment of peadiatric lymphomas rely on metabolic information from 18 F-FDG PET scans [58] [59] [60] [61] [62] [63] . Lack of metabolic response on interim 18 F-FDG PET/CT scans after 2 cycles of chemotherapy is being used by many investigators as a criterion for early intensification of chemotherapy. Thus, while the medical community is in the process of assessing the value of diffusion-weighted sequences and apparent diffusion coefficients (ADC values) for treatment monitoring of paediatric lymphomas, 18 F-FDG PET/MR with accelerated acquisition protocols may represent a compromise toward accurate diagnoses with the least possible radiation exposure.
Conclusion
We increased the time-and cost-efficiency of whole-body PET/MR scans by replacing traditional STIR scans with contrast-enhanced, breath-hold T1-weighted FSPGR scans. This efficient imaging approach improved the feasibility of PET/ MR as a monitoring option for paediatric tumours, with reduced radiation exposure compared to PET/CT.
